NASDAQ:TNXP Tonix Pharmaceuticals (TNXP) Stock Price, News & Analysis $11.72 -0.57 (-4.64%) Closing price 04:00 PM EasternExtended Trading$11.79 +0.07 (+0.59%) As of 07:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Tonix Pharmaceuticals Stock (NASDAQ:TNXP) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Tonix Pharmaceuticals alerts:Sign Up Key Stats Today's Range$11.51▼$12.2050-Day Range$12.03▼$16.0852-Week Range$11.51▼$69.97Volume739,785 shsAverage Volume422,904 shsMarket Capitalization$186.82 millionP/E RatioN/ADividend YieldN/APrice Target$22.00Consensus RatingModerate Buy Company Overview Tonix Pharmaceuticals is a clinical-stage biotechnology company focused on developing therapeutics for central nervous system disorders, immunology and rare diseases. The company’s pipeline includes small-molecule and biologic product candidates designed to address conditions such as fibromyalgia, post-traumatic stress disorder (PTSD) and other chronic pain syndromes, as well as vaccines for potential viral and biothreat agents. Among Tonix’s lead programs is TNX-102 SL, a sublingual formulation of cyclobenzaprine being evaluated for the treatment of fibromyalgia and PTSD. The company is conducting late-stage clinical trials to assess safety and efficacy in people who experience chronic pain and disrupted sleep due to these conditions. In addition to its CNS portfolio, Tonix is advancing live-virus vaccine candidates against orthopoxviruses, including those that could be used for smallpox or monkeypox, and is exploring development of vaccines against other biothreat agents. Headquartered in New York, Tonix Pharmaceuticals leverages in-house research and collaborations with academic institutions and government agencies to advance its pipeline. The company was co-founded and is led by Seth H. Lederman, M.D., who serves as President and Chief Executive Officer. Under Dr. Lederman’s direction, Tonix continues to progress multiple programs through clinical development while maintaining a focus on unmet medical needs in both therapeutic and vaccine arenas.AI Generated. May Contain Errors. Read More Tonix Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks80th Percentile Overall ScoreTNXP MarketRank™: Tonix Pharmaceuticals scored higher than 80% of companies evaluated by MarketBeat, and ranked 147th out of 869 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingModerate Buy Consensus RatingTonix Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 1 strong buy rating, 1 buy rating, no hold ratings, and 1 sell rating.Upside PotentialTonix Pharmaceuticals has a consensus price target of $22.00, representing about 87.7% upside from its current price of $11.72.Amount of Analyst CoverageTonix Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.Read more about Tonix Pharmaceuticals' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Tonix Pharmaceuticals are expected to grow in the coming year, from ($9.94) to ($6.58) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Tonix Pharmaceuticals is -0.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Tonix Pharmaceuticals is -0.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTonix Pharmaceuticals has a P/B Ratio of 0.61. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Tonix Pharmaceuticals' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted15.00% of the float of Tonix Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverTonix Pharmaceuticals has a short interest ratio ("days to cover") of 5.08.Change versus previous monthShort interest in Tonix Pharmaceuticals has recently decreased by 10.15%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTonix Pharmaceuticals does not currently pay a dividend.Dividend GrowthTonix Pharmaceuticals does not have a long track record of dividend growth. News and Social Media2.7 / 5News Sentiment0.27 News SentimentTonix Pharmaceuticals has a news sentiment score of 0.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.78 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for Tonix Pharmaceuticals this week, compared to 5 articles on an average week.Search InterestOnly 18 people have searched for TNXP on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows10 people have added Tonix Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days. Company Ownership3.6 / 5Insider TradingAcquiring Shares Net Insider BuyingOver the last three months, insiders have purchased a net $223,350.00 in company stock, which represents 0.1196% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Tonix Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $223,350.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders2.00% of the stock of Tonix Pharmaceuticals is held by insiders.Percentage Held by Institutions82.26% of the stock of Tonix Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Tonix Pharmaceuticals' insider trading history. Receive TNXP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tonix Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TNXP Stock News HeadlinesTonix Advances TNX-102 SL Into Phase 2 Depression Trial, Drawing Investor FocusJune 2 at 12:50 PM | tipranks.comTonix Pharmaceuticals Presented Retrospective U.S. Real-World Claims Analysis of Opioid Use in Patients with Fibromyalgia at the 2026 American Society of Clinical ...May 29, 2026 | markets.businessinsider.comRead this warning immediatelyPorter Stansberry, founder of one of the world's largest financial research firms, says he's breaking the biggest story of his 26-year career. A famous historian whose books have sold over 45 million copies in 65 languages is warning of a structural shift so large it has only one historical parallel - 1776. One Stanford economist calls it 'the biggest change ever - bigger than electricity, bigger than the steam engine.' Stansberry outlines the stocks to buy, the stocks to sell, and three money moves to position yourself on the right side of this shift.June 2 at 1:00 AM | Porter & Company (Ad)Tonix Pharmaceuticals Presented Retrospective U.S. Real-World Claims Analysis of Opioid Use in Patients with Fibromyalgia at the 2026 American Society of Clinical Psychopharmacology (ASCP) Annual MeetingMay 28, 2026 | finance.yahoo.comTonix Pharmaceuticals Presented Retrospective U.S. Real-World Claims Analysis of Opioid Use in Patients with Fibromyalgia at the 2026 American Society of Clinical Psychopharmacology (ASCP) Annual MeetingMay 28, 2026 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: Daxor (DXR) and Tonix Pharma (TNXP)May 27, 2026 | theglobeandmail.comTonix Pharmaceuticals Announces Publication of Phase 1 Clinical Data of TNX-1500, an Fc-Modified anti-CD40L (CD154) Monoclonal Antibody, in the Peer-Reviewed Journal of ...May 27, 2026 | markets.businessinsider.comTonix Pharmaceuticals Announces Publication of Phase 1 Clinical Data of TNX-1500, an Fc-Modified anti-CD40L (CD154) Monoclonal Antibody, in the Peer-Reviewed Journal of Clinical ImmunologyMay 27, 2026 | finance.yahoo.comSee More Headlines TNXP Stock Analysis - Frequently Asked Questions How have TNXP shares performed this year? Tonix Pharmaceuticals' stock was trading at $15.62 at the start of the year. Since then, TNXP stock has decreased by 25.0% and is now trading at $11.72. How were Tonix Pharmaceuticals' earnings last quarter? Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) issued its earnings results on Monday, May, 11th. The company reported ($2.93) EPS for the quarter, missing the consensus estimate of ($2.54) by $0.39. The firm had revenue of $6.88 million for the quarter, compared to analysts' expectations of $6.13 million. Tonix Pharmaceuticals had a negative net margin of 839.52% and a negative trailing twelve-month return on equity of 67.65%. When did Tonix Pharmaceuticals' stock split? Tonix Pharmaceuticals's stock reverse split on the morning of Wednesday, February 5th 2025.The 1-100 reverse split was announced on Monday, February 3rd 2025. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, February 4th 2025. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split. Who are Tonix Pharmaceuticals' major shareholders? Top institutional investors of Tonix Pharmaceuticals include Bank of America Corp DE (0.38%), Bank of New York Mellon Corp (0.23%) and SJS Investment Consulting Inc. (0.07%). Insiders that own company stock include Seth Lederman and Carolyn E Taylor. View institutional ownership trends. How do I buy shares of Tonix Pharmaceuticals? Shares of TNXP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Tonix Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Tonix Pharmaceuticals investors own include Meta Platforms (META), Digital Turbine (APPS), NIO (NIO), Sorrento Therapeutics (SRNE) and Company Calendar Last Earnings5/11/2026Today6/02/2026Next Earnings (Estimated)8/10/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (8m+) 1-Year History Jun 25 Sep 25 Dec 25 Mar 26 Jun 26 TNXP's financial health is in the Yellow zone, according to TradeSmith. TNXP has been in this zone for over 8 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:TNXP CIK1430306 Webwww.tonixpharma.com Phone(862) 799-8599Fax212-923-5700Employees50Year Founded2007Price Target and Rating Average Price Target for Tonix Pharmaceuticals$22.00 High Price Target$22.00 Low Price Target$22.00 Potential Upside/Downside+87.7%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($14.36) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$124.02 million Net Margins-839.52% Pretax Margin-839.52% Return on Equity-67.65% Return on Assets-60.47% Debt Debt-to-Equity RatioN/A Current Ratio6.99 Quick Ratio6.86 Sales & Book Value Annual Sales$13.11 million Price / Sales14.25 Cash FlowN/A Price / Cash FlowN/A Book Value$19.17 per share Price / Book0.61Miscellaneous Outstanding Shares15,940,000Free Float15,622,000Market Cap$186.82 million OptionableNot Optionable Beta1.67 Social Links 5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NASDAQ:TNXP) was last updated on 6/2/2026 by MarketBeat.com Staff. From Our PartnersTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredHow to claim a stake in SpaceX before the June 12 IPOSpaceX is expected to go public on June 12 - and for the first time, everyday investors may have a way in befo...Brownstone Research | SponsoredYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Be...Banyan Hill Publishing | SponsoredSecret behind near perfectly timed stock trades…?After 20 years of professional trading, Ross Givens says this is the single most lucrative market strategy he ...Traders Agency | SponsoredI paid $5,000 to hear Elon say thisOne investor paid $5,000 to be in a private room with Elon Musk in Los Angeles - and what he heard confirmed a...InvestorPlace | SponsoredPresident Trump just sparked a stock market MELT UPThe real reason Musk, Huang, Cook, and Fink just flew to Beijing Last week, the CEOs of Nvidia, Apple, Spac...Stansberry Research | SponsoredGold hit $4,500 - but these miners haven't caught up yet$9 trillion in U.S. debt must be refinanced in 2026 - at current rates - while the largest foreign buyers of T...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tonix Pharmaceuticals Holding Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tonix Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
